187 related articles for article (PubMed ID: 38671465)
21. PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression.
Lakhia R; Ramalingam H; Chang CM; Cobo-Stark P; Biggers L; Flaten A; Alvarez J; Valencia T; Wallace DP; Lee EC; Patel V
Nat Commun; 2022 Aug; 13(1):4765. PubMed ID: 35965273
[TBL] [Abstract][Full Text] [Related]
22. Channel Function of Polycystin-2 in the Endoplasmic Reticulum Protects against Autosomal Dominant Polycystic Kidney Disease.
Padhy B; Xie J; Wang R; Lin F; Huang CL
J Am Soc Nephrol; 2022 Aug; 33(8):1501-1516. PubMed ID: 35835458
[TBL] [Abstract][Full Text] [Related]
23. EASL Clinical Practice Guidelines on the management of cystic liver diseases.
;
J Hepatol; 2022 Oct; 77(4):1083-1108. PubMed ID: 35728731
[TBL] [Abstract][Full Text] [Related]
24. Abnormal accumulation of OFD1 in endometrial cancer with poor prognosis inhibits ciliogenesis.
Kojima R; Hassan E; Ozawa F; Yamada-Namikawa C; Ogawa S; Mase S; Goto S; Nishikawa R; Inagaki H; Kato Y; Sugiura-Ogasawara M
Oncol Lett; 2022 Jul; 24(1):214. PubMed ID: 35720483
[TBL] [Abstract][Full Text] [Related]
25. Abdominal wall hernia is a frequent complication of polycystic liver disease and associated with hepatomegaly.
Barten TRM; Bökkerink RMP; Venderink W; Gevers TJG; Ten Broek RPG; Drenth JPH
Liver Int; 2022 Apr; 42(4):871-878. PubMed ID: 35129293
[TBL] [Abstract][Full Text] [Related]
26. Autophagy promotes hepatic cystogenesis in polycystic liver disease by depletion of cholangiocyte ciliogenic proteins.
Masyuk AI; Masyuk TV; Trussoni CE; Pirius NE; LaRusso NF
Hepatology; 2022 May; 75(5):1110-1122. PubMed ID: 34942041
[TBL] [Abstract][Full Text] [Related]
27. Emerging View on the Molecular Functions of Sec62 and Sec63 in Protein Translocation.
Jung SJ; Kim H
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884562
[TBL] [Abstract][Full Text] [Related]
28. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
Suwabe T; Barrera FJ; Rodriguez-Gutierrez R; Ubara Y; Hogan MC
PLoS One; 2021; 16(9):e0257606. PubMed ID: 34559824
[TBL] [Abstract][Full Text] [Related]
30. Clinical features of autosomal recessive polycystic kidney disease in the Japanese population and analysis of splicing in PKHD1 gene for determination of phenotypes.
Ishiko S; Morisada N; Kondo A; Nagai S; Aoto Y; Okada E; Rossanti R; Sakakibara N; Nagano C; Horinouchi T; Yamamura T; Ninchoji T; Kaito H; Hamada R; Shima Y; Nakanishi K; Matsuo M; Iijima K; Nozu K
Clin Exp Nephrol; 2022 Feb; 26(2):140-153. PubMed ID: 34536170
[TBL] [Abstract][Full Text] [Related]
31. Polycystin-1 dependent regulation of polycystin-2 via GRP94, a member of HSP90 family that resides in the endoplasmic reticulum.
Yao Q; Outeda P; Xu H; Walker R; Basquin D; Qian F; Cebotaru L; Watnick T; Cebotaru V
FASEB J; 2021 Oct; 35(10):e21865. PubMed ID: 34486178
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen for the treatment of polycystic liver disease: A case report.
Aapkes SE; Bernts LHP; van den Berg M; Gansevoort RT; Drenth JPH
Medicine (Baltimore); 2021 Aug; 100(32):e26797. PubMed ID: 34397882
[TBL] [Abstract][Full Text] [Related]
33. Expanding the variability of the ADPKD-GANAB clinical phenotype in a family of Italian ancestry.
Delbarba E; Econimo L; Dordoni C; Martin E; Mazza C; Savoldi G; Alberici F; Scolari F; Izzi C
J Nephrol; 2022 Mar; 35(2):645-652. PubMed ID: 34357571
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
[TBL] [Abstract][Full Text] [Related]
35. Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patients.
Oh YK; Park HC; Ryu H; Kim YC; Oh KH
Korean J Intern Med; 2021 Jul; 36(4):767-779. PubMed ID: 34237823
[TBL] [Abstract][Full Text] [Related]
36. Gender-Dependent Phenotype in Polycystic Kidney Disease Is Determined by Differential Intracellular Ca
Talbi K; Cabrita I; Schreiber R; Kunzelmann K
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199520
[TBL] [Abstract][Full Text] [Related]
37. Inward Ca
Kleene SJ; Kleene NK
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1165-F1173. PubMed ID: 33969696
[TBL] [Abstract][Full Text] [Related]
38. Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease.
Kataoka H; Watanabe S; Sato M; Manabe S; Makabe S; Akihisa T; Ushio Y; Iwasa N; Yoshida R; Tsuchiya K; Nitta K; Mochizuki T
Hepatol Int; 2021 Jun; 15(3):791-803. PubMed ID: 33811288
[TBL] [Abstract][Full Text] [Related]
39. Patients with Protein-Truncating
Lanktree MB; Guiard E; Akbari P; Pourafkari M; Iliuta IA; Ahmed S; Haghighi A; He N; Song X; Paterson AD; Khalili K; Pei YPC
Clin J Am Soc Nephrol; 2021 Mar; 16(3):374-383. PubMed ID: 33602752
[TBL] [Abstract][Full Text] [Related]
40. Polycystic liver disease genes: Practical considerations for genetic testing.
Boerrigter MM; Bongers EMHF; Lugtenberg D; Nevens F; Drenth JPH
Eur J Med Genet; 2021 Mar; 64(3):104160. PubMed ID: 33556586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
